Drug Discovery World
SEPTEMBER 16, 2022
Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal antibody for any skin disease in patients aged six months to six years. It’s also incredibly stressful for their families, particularly as children’s sleep is so disturbed. .
The Pharma Data
MARCH 23, 2022
The only large-scale prospective study in dermatology designed to generate key disease insights among Black, Hispanic, Asian, Indigenous and other people of color Study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities. 11 TREMFYA is approved in the U.S.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
MARCH 3, 2022
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Broad Clinical Trial Landscape. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications.
The Pharma Data
JANUARY 24, 2021
It will be run through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), with support from the Bill & Melinda Gates Foundation. All participants randomized to receive either 4,200 mg of bamlanivimab, Lilly’s neutralizing antibody, or placebo. Non-COVID-19-Related.
The Pharma Data
DECEMBER 17, 2020
Goater is CEO at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies. Martin Carter Professor in Clinical Investigation and Head of the Laboratory of Investigative Dermatology at The Rockefeller University and Weinblatt is the co-director of Clinical Rheumatology at the Brigham and Women’s Hospital.
The Pharma Data
APRIL 4, 2023
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Merck has the industry’s largest immuno-oncology clinical research program.
The Pharma Data
JULY 8, 2021
KEYTRUDA has shown meaningful efficacy in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma that cannot be cured by surgery or radiation,” said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories.
Expert insights. Personalized for you.
52 
Let's personalize your content